| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1039662807 |
| P356 | DOI | 10.2165/00023210-200519050-00002 |
| P698 | PubMed publication ID | 15907150 |
| P50 | author | Dan J. Stein | Q5213742 |
| Jacqueline Müller-Nordhorn | Q56957969 | ||
| Liezl Koen | Q90171143 | ||
| Soraya Seedat | Q42573059 | ||
| P2860 | cites work | Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. | Q53986746 |
| Buspirone in social phobia. | Q54044366 | ||
| Paroxetine in social anxiety disorder: a randomized placebo-controlled study | Q56949733 | ||
| Fluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents | Q61948545 | ||
| Fluoxetine for the treatment of social phobia | Q68047584 | ||
| Fluoxetine in social phobia | Q68079804 | ||
| Meta-analysis of cognitive-behavioral treatments for social phobia | Q71549532 | ||
| Effect of pindolol on stress-related disturbances of musical performance: preliminary communication | Q71690665 | ||
| Sertraline for social phobia: a double-blind, placebo-controlled crossover study | Q72006198 | ||
| Physical disability and social phobia | Q72467661 | ||
| Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine | Q72561763 | ||
| Behavioral treatment of childhood social phobia | Q73356187 | ||
| The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study | Q73402434 | ||
| Moclobemide in social phobia: a controlled dose-response trial | Q73552399 | ||
| Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study | Q73552403 | ||
| Placebo-controlled trial of moclobemide in social phobia | Q74421981 | ||
| Nefazodone in social phobia | Q74619376 | ||
| Low dose selegiline (L-Deprenyl) in social phobia | Q74761893 | ||
| Mini-SPIN: A brief screening assessment for generalized social anxiety disorder | Q74826607 | ||
| Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders | Q78195316 | ||
| Group and individual cognitive-behavioral therapy for childhood anxiety disorders: a randomized trial | Q78558405 | ||
| World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders | Q22305681 | ||
| A rating scale for depression | Q24564540 | ||
| Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine | Q28189715 | ||
| Effect of beta-blockade during bowling competitions | Q28316483 | ||
| The emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation | Q28369864 | ||
| Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group | Q28378567 | ||
| The assessment of anxiety states by rating | Q29614719 | ||
| Effect of beta blockade and beta stimulation on stage fright | Q30411905 | ||
| Effect of oxprenolol on stage-fright in musicians | Q30525700 | ||
| Letter: Beta-blocking agents in the treatment of catecholamine-induced symptoms in musicians | Q30531715 | ||
| Stage Fright in Musicians: A Model Illustrating the Effect of Beta Blockers | Q30535027 | ||
| Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study | Q31825606 | ||
| Pharmacotherapy for social phobia | Q33208084 | ||
| Treatment of social phobia with gabapentin: a placebo-controlled study | Q33420919 | ||
| Social anxiety disorder: designing a pharmacologic treatment strategy | Q33639964 | ||
| Psychometric properties of the Social Phobia Inventory (SPIN). New self-rating scale | Q33903235 | ||
| Bupropion-SR in treatment of social phobia | Q33926160 | ||
| Social anxiety disorder: an unrecognized problem in primary care | Q33934827 | ||
| Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy | Q33958852 | ||
| Paroxetine for social anxiety and alcohol use in dual-diagnosed patients | Q34106340 | ||
| Scrutinizing the relationship between shyness and social phobia. | Q34156690 | ||
| Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study | Q34163102 | ||
| Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study | Q43990354 | ||
| Combined psychoeducation and treatment with selective serotonin reuptake inhibitors for youth with generalized social anxiety disorder | Q43996149 | ||
| Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder | Q44072853 | ||
| Phobia: prevalence and risk factors | Q44110931 | ||
| Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings | Q44233161 | ||
| Efficacy of olanzapine in social anxiety disorder: a pilot study | Q44263553 | ||
| Effects of positive GABA(A) modulators on a multiple-component, repeated-acquisition test of spatial learning | Q44308870 | ||
| A large open multicentre trial of clomipramine (Anafranil) in the management of phobic disorders | Q44361786 | ||
| Exposure therapy and sertraline in social phobia: I-year follow-up of a randomised controlled trial | Q44385600 | ||
| Citalopram treatment of social anxiety disorder with comorbid major depression | Q44486778 | ||
| Phenelzine efficacy in refractory social anxiety disorder: a case series | Q44530821 | ||
| An open clinical trial of reboxetine in the treatment of social phobia | Q44550804 | ||
| Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial | Q44646501 | ||
| Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine | Q45012914 | ||
| Escitalopram in the treatment of social anxiety disorder: analysis of efficacy for different clinical subgroups and symptom dimensions | Q45219380 | ||
| Functional brain imaging and pharmacotherapy in social phobia: single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram | Q46332121 | ||
| The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomized controlled trials. | Q46544189 | ||
| Psychometric properties of the Liebowitz Social Anxiety Scale | Q47605551 | ||
| Dismantling Cognitive-Behavioral Group Therapy for social phobia | Q47642167 | ||
| Algorithm for the pharmacotherapy of anxiety disorders | Q47764409 | ||
| The Zurich study. XX. Social phobia and agoraphobia | Q48879583 | ||
| Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor | Q48887380 | ||
| Effectiveness of an empirically supported treatment for social phobia in the field. | Q51017177 | ||
| Social phobia: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study. | Q51034646 | ||
| Social fears and social phobia in a community sample of adolescents and young adults: prevalence, risk factors and co-morbidity. | Q51090522 | ||
| Social phobia subtypes in the National Comorbidity Survey. | Q51097770 | ||
| The Brief Social Phobia Scale: a psychometric evaluation. | Q51107705 | ||
| Treatment of social phobia with clonazepam and placebo. | Q51138932 | ||
| Tranylcypromine in social phobia. | Q51186659 | ||
| Antidepressant specificity in atypical depression. | Q51190598 | ||
| The effect of beta adrenergic blocking drugs on speakers' performance and memory. | Q51241988 | ||
| State-dependent effects of atypical benzodiazepine-receptor agonists. | Q51603275 | ||
| Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. | Q52048160 | ||
| Imipramine in the treatment of social phobia. | Q53956216 | ||
| Pharmacological treatment of social anxiety disorder: a meta-analysis | Q34219988 | ||
| A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care | Q34224290 | ||
| Phenelzine v imipramine in atypical depression. A preliminary report | Q34257823 | ||
| Treatment of anxiety disorders to remission. | Q34295866 | ||
| Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial | Q34334039 | ||
| Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia | Q34356032 | ||
| Phenelzine vs atenolol in social phobia. A placebo-controlled comparison | Q34374338 | ||
| Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey | Q34379497 | ||
| The role of selective serotonin reuptake inhibitors in reducing alcohol consumption | Q34390015 | ||
| Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia | Q34399388 | ||
| Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome | Q34484694 | ||
| Pharmacotherapy of social anxiety disorder | Q34500654 | ||
| Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome | Q34506283 | ||
| Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia | Q34516106 | ||
| Hepatic adverse reactions associated with nefazodone | Q34523391 | ||
| Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study | Q34536464 | ||
| Social phobia. Comorbidity and morbidity in an epidemiologic sample | Q34553212 | ||
| Social phobia | Q34559590 | ||
| Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction | Q34738402 | ||
| Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial | Q34751994 | ||
| Hyperhidrosis in social anxiety disorder | Q35034405 | ||
| A review of 19 double-blind placebo-controlled studies in social anxiety disorder (social phobia). | Q35073851 | ||
| Non-pharmacologic treatments for social anxiety disorder | Q35209667 | ||
| Effect of beta blockade on singing performance | Q36414138 | ||
| Psychological and pharmacological treatments of social phobia: a meta-analysis | Q40704680 | ||
| Sertraline in children and adolescents with social anxiety disorder: an open trial | Q40708382 | ||
| Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment | Q40735804 | ||
| Venlafaxine in social phobia. | Q41147375 | ||
| Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study | Q41665011 | ||
| Paroxetine (Paxil, Seroxat): increased risk of suicide in pediatric patients | Q42124181 | ||
| A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. | Q42170403 | ||
| Open trial of interpersonal psychotherapy for the treatment of social phobia | Q42613281 | ||
| Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. | Q42621508 | ||
| Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. | Q42671280 | ||
| Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia | Q42677098 | ||
| Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder | Q43697585 | ||
| Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study | Q43752226 | ||
| The selective serotonin reuptake inhibitor paroxetine is effective in more generalized and in less generalized social anxiety disorder | Q43802625 | ||
| P433 | issue | 5 | |
| P921 | main subject | social anxiety disorder | Q281928 |
| P304 | page(s) | 377-391 | |
| P577 | publication date | 2005-01-01 | |
| P1433 | published in | CNS Drugs | Q5013183 |
| P1476 | title | Social anxiety disorder : current treatment recommendations | |
| P478 | volume | 19 |
| Q46747041 | A 2010 evidence-based algorithm for the pharmacotherapy of social anxiety disorder |
| Q57738659 | Anxiety disorders: under-diagnosed and insufficiently treated |
| Q24656009 | Efficacy and tolerability of second-generation antidepressants in social anxiety disorder |
| Q38220450 | Evidence-based treatment of anxiety disorders |
| Q37399886 | Recent advances in understanding and treating social anxiety disorder. |
| Q37690425 | The Efficacy of Augment of D-Cycloserine and Cognitive-behavioral Therapy on Adolescent with one Type of Anxiety Disorders: A Double-blind Randomized Controlled Trial |
| Q28300843 | The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects |
| Q36419538 | Treatment of anxiety disorders with venlafaxine XR. |
Search more.